Esophageal Carcinoma

1. Disease Information

Overview

Esophageal carcinoma (EC) is a highly aggressive malignancy of the esophagus and one of the most lethal cancers worldwide, with approximately 511,054 new cases and 445,391 deaths globally in 2022 (qi2024globalesophagealcancer pages 1-2). It is the seventh leading cause of cancer-related mortality globally, with 5-year survival rates of only 10–30% (zhang2026esophagealcancerfrom pages 1-2). EC encompasses two principal histological subtypes with distinct epidemiological, etiological, and molecular profiles: esophageal squamous cell carcinoma (ESCC), accounting for approximately 80% of cases globally, and esophageal adenocarcinoma (EAC), whose incidence is rising in Western countries (zhang2026esophagealcancerfrom pages 1-2, sheikh2023currentstatusand pages 15-16).

Key Identifiers

• ICD-10: C15 (Malignant neoplasm of esophagus); C15.0–C15.9 for subsites
• ICD-11: 2B70 (Malignant neoplasms of oesophagus)
• MeSH: D004938 (Esophageal Neoplasms)
• MONDO: MONDO_0019086 (carcinoma of esophagus); MONDO_0005580 (esophageal squamous cell carcinoma); MONDO_0005028 (esophageal adenocarcinoma) (OpenTargets Search: esophageal carcinoma)
• OMIM: Not a single-gene Mendelian disorder; ESCC/EAC arise from complex multifactorial causes

Common Synonyms

Esophageal cancer, oesophageal carcinoma, cancer of the esophagus, esophageal malignancy, gullet cancer.

Data Sources

Information is derived from aggregated disease-level resources including GLOBOCAN, the Global Burden of Disease (GBD) Study, SEER, TCGA, and published clinical/epidemiological literature.

2. Etiology

Disease Causal Factors

ESCC and EAC have distinct etiological pathways. ESCC develops through a multistep progression from normal squamous epithelium through basal cell hyperplasia and dysplasia to carcinoma, driven by chronic mucosal irritation. EAC evolves from Barrett's esophagus (BE) induced by chronic gastroesophageal reflux disease (GERD), following a stepwise progression: GERD → BE → low-grade dysplasia → high-grade dysplasia → adenocarcinoma (zhang2026esophagealcancerfrom pages 1-2, li2023molecularbiologyand pages 1-2).

Risk Factors

Genetic Risk Factors

• TP53 mutations are the most frequently altered gene in ESCC (~90% of patients) and are prevalent in EAC, with 46% of BE progressors carrying TP53 mutations compared to 5% of nonprogressors (zhang2026esophagealcancerfrom pages 6-7).
• CDKN2A inactivation via promoter methylation is detected in nearly all individuals developing dysplasia (zhang2026esophagealcancerfrom pages 9-10).
• ADH1B polymorphisms (alcohol dehydrogenase 1B) modify acetaldehyde exposure and alcohol-related carcinogenic risk, representing a key genetic susceptibility marker (OpenTargets Search: esophageal carcinoma).
• Susceptibility loci include variants in CTLA-4, SLC39A6, PLCE1, FOXF, BARX1, and ABCC5 (zhang2026esophagealcancerfrom pages 2-3, li2023molecularbiologyand pages 6-8).
• Hereditary conditions: Tylosis (focal non-epidermolytic palmoplantar keratoderma) is strongly associated with ESCC risk.

Environmental Risk Factors

• ESCC: Alcohol consumption, tobacco/opium smoking, dietary carcinogens (nitrosamines), hot beverages, micronutrient deficiencies, betel quid chewing, poor oral hygiene, low socioeconomic status (zhang2026esophagealcancerfrom pages 1-2, sheikh2023currentstatusand pages 15-16, liu2023epidemiologyofesophageal pages 8-9).
• EAC: Obesity, GERD, smoking, male sex, Caucasian ethnicity, high BMI (li2023molecularbiologyand pages 1-2, sheikh2023currentstatusand pages 15-16).
• In 2019, smoking accounted for 50.1% of DALYs for EC in males and 11.3% in females; alcohol use accounted for 29.6% in males and 5.1% in females; high BMI accounted for 18.8% in males and 19.3% in females (ilic2024globalburdenof pages 6-10).

Protective Factors

• Diets rich in fruits and vegetables reduce risk: low-fruit diet accounted for 10.1–12.6% of DALYs (ilic2024globalburdenof pages 6-10).
• Helicobacter pylori infection has been paradoxically associated with reduced EAC risk.
• Aspirin and proton pump inhibitor use show chemoprevention potential for EAC (sheikh2023currentstatusand pages 15-16).

Gene-Environment Interactions

ADH1B genetic variants interact with alcohol exposure to modulate acetaldehyde accumulation and carcinogenic risk, particularly in East Asian populations (OpenTargets Search: esophageal carcinoma). Tobacco smoke exposure combined with TP53 polymorphisms significantly increases ESCC risk (zhang2026esophagealcancerfrom pages 2-3).

3. Phenotypes

Symptoms and Clinical Signs

• Dysphagia (progressive, initially to solids then liquids) — HP:0002015
• Odynophagia (painful swallowing) — HP:0200136
• Unintended weight loss — HP:0001824
• Chest pain/retrosternal discomfort — HP:0100749
• Hoarseness (recurrent laryngeal nerve involvement) — HP:0001609
• Chronic cough — HP:0012735
• Hematemesis/melena (GI bleeding) — HP:0002239
• Fatigue — HP:0012378
• Iron deficiency anemia — HP:0001891

Phenotype Characteristics

• Age of onset: Predominantly adult-onset (>50 years), with peak incidence in the 60–70 age group (ilic2024globalburdenof pages 4-6).
• Severity: Generally severe; most patients present at advanced stages.
• Progression: Progressive; early-stage disease is often asymptomatic.
• Frequency: Dysphagia is present in >90% of symptomatic patients at diagnosis.

Quality of Life Impact

EC significantly impairs quality of life through dysphagia, nutritional compromise, and treatment-related morbidity. The SANO trial demonstrated that active surveillance after complete clinical response to chemoradiotherapy showed noninferior overall survival and better short-term quality of life compared to surgery at 2 years (fick2024immunotherapyforresectable pages 9-10).

4. Genetic/Molecular Information

Key Somatic Mutations (by subtype)

• ESCC: TP53 (~90%), NOTCH1, NFE2L2/KEAP1, KMT2D, PIK3CA, CDKN2A, FBXW7, EP300 (zhang2026esophagealcancerfrom pages 2-3, zhang2026esophagealcancerfrom pages 6-7).
• EAC: TP53, SMAD4, CDKN2A, ARID1A with frequent amplifications of ERBB2 (21.8%), CCNE1 (12.6%), GATA4 (10.3%), and KRAS (10.3%) (zhang2026esophagealcancerfrom pages 9-10, li2023molecularbiologyand pages 6-8).

Pathogenic Variants

• TP53 mutations are predominantly missense/nonsense, occurring throughout the DNA-binding domain; somatic origin in tumors; associated with genomic instability and impaired apoptosis (zhang2026esophagealcancerfrom pages 6-7).
• CDKN2A inactivation occurs through promoter hypermethylation, homozygous deletion, or LOH; detectable in nearly all dysplasia cases (zhang2026esophagealcancerfrom pages 9-10).
• ERBB2 amplification in EAC (HER2+) occurs in 15–29% of cases and is an FDA-approved companion diagnostic for trastuzumab therapy (rai2023biomarkersforearly pages 8-9).
• Tumor mutation burden (TMB) in ESCC cell lines ranges from 48.7 to 70.4 mutations/Mb, with signature 3 (homologous recombination deficiency) being significantly enriched (zhang2025thegenomiclandscape pages 4-7).

Epigenetic Information

• Genome-wide hypomethylation in cancer tissues and promoter hypermethylation-mediated silencing of tumor suppressor genes (CDKN2A, APC) are characteristic (zhang2026esophagealcancerfrom pages 8-9, zhang2026esophagealcancerfrom pages 9-10).
• APC promoter hypermethylation is observed in up to 92% of adenocarcinomas (zhang2026esophagealcancerfrom pages 9-10).
• MicroRNA dysregulation and DNA methylation patterns vary with each phase of BE, LGD, HGD, early EAC, and invasive EAC (li2023molecularbiologyand pages 16-17).
• RNA m6A demethylation affecting LINC00022 and DNMT1-microRNA126 circuits contribute to growth via ADAM9-EGFR-AKT signaling (zhang2026esophagealcancerfrom pages 30-31).
• A core gene regulatory network involving TP63, SOX2, and KLF5 regulates chromatin accessibility in ESCC (zhang2026esophagealcancerfrom pages 9-10).

Chromosomal Abnormalities

• Chromosomal instability (CIN) is a hallmark of both subtypes. Gene amplifications are frequent in 57% of EAC cases (zhang2026esophagealcancerfrom pages 9-10).
• Copy number variations affect SOX2, NFE2L2, and CDKN2A, progressively accumulating from early dysplasia stages (zhang2026esophagealcancerfrom pages 8-9).
• LOH at APC locus and structural variations affecting CDKN2A and NOTCH1 are recurrent (zhang2026esophagealcancerfrom pages 9-10).

The following table summarizes key disease-target associations from OpenTargets and literature:

Table: This table summarizes major disease-target associations for esophageal carcinoma by integrating OpenTargets association scores with recent literature on subtype biology and therapeutic relevance. It is useful for prioritizing biomarkers and targets across ESCC and EAC, including established immunotherapy and HER2-directed axes as well as investigational pathways.

5. Environmental Information

Environmental Factors

Environmental carcinogens include nitrosamines from dietary sources, air pollution, and occupational exposures. Chronic acid and bile reflux damage the esophageal epithelium, generating reactive oxygen species causing DNA double-strand breaks (maslenkina2023signalingpathwaysin pages 14-16). Nitrite exposure and high-fat diets are additional contributing factors (zhang2026esophagealcancerfrom pages 6-7).

Lifestyle Factors

Tobacco smoking and alcohol consumption are the dominant modifiable risk factors for ESCC, causing ~90% of cases in the US and Western countries (jiang2023globaltrendsin pages 12-13). Obesity is a primary risk factor for EAC. Hot beverage consumption, poor oral hygiene, and sedentary lifestyle contribute to risk (liu2023epidemiologyofesophageal pages 8-9).

Infectious Agents

• HPV (Human Papillomavirus): Circulating HPV DNA is associated with disease severity in some ESCC cohorts (rai2023biomarkersforearly pages 6-8).
• EBV (Epstein-Barr Virus): EBV status is under investigation as a biomarker for predicting immunotherapy response (fick2024immunotherapyforresectable pages 4-5).

6. Mechanism / Pathophysiology

Molecular Pathways

• PI3K/AKT pathway: Overactivation drives cell proliferation, survival, invasion, and metastasis (zhang2026esophagealcancerfrom pages 6-7).
• Notch signaling: NOTCH1 mutations provide competitive advantage in normal epithelium; overactivation in ESCC promotes angiogenesis through VEGF, ANGPT2, and CXCL1 upregulation (zhang2026esophagealcancerfrom pages 6-7, zhang2026esophagealcancerfrom pages 8-9). KEGG: hsa04330.
• NRF2/KEAP1 pathway: NRF2 pathway activation (42.9% mutation rate in ESCC cell lines) causes oxidative stress-related DNA damage in neighboring cells (zhang2025thegenomiclandscape pages 4-7, zhang2026esophagealcancerfrom pages 6-7). GO:0006979 (response to oxidative stress).
• Hippo, RTK-Ras, and Wnt pathways showed mutations across all ESCC cell lines analyzed (zhang2025thegenomiclandscape pages 4-7).
• NF-κB signaling: Activated by deoxycholic acid in Barrett's esophagus; IL-6/STAT3 signaling mediates apoptotic resistance (maslenkina2023signalingpathwaysin pages 14-16).
• VEGF signaling: Induces epithelial-to-mesenchymal transition (EMT) (maslenkina2023signalingpathwaysin pages 14-16).

Cellular Processes

• Apoptosis evasion: TP53 loss impairs apoptotic signaling (GO:0006915).
• Cell cycle dysregulation: CDKN2A loss leads to loss of G1/S checkpoint and cell over-proliferation (GO:0007049) (zhang2026esophagealcancerfrom pages 6-7).
• Epithelial-mesenchymal transition (EMT): Key for invasion and metastasis (GO:0001837).
• Angiogenesis: NOTCH-mediated upregulation of VEGF and ANGPT2 (GO:0001525) (zhang2026esophagealcancerfrom pages 8-9).

Immune System Involvement

The tumor microenvironment shifts from early immune surveillance dominated by CD8+ T cells and NK cells to later immunosuppressive conditions characterized by M2 tumor-associated macrophages, regulatory T cells, myeloid-derived suppressor cells (MDSCs), T-cell exhaustion, and cancer-associated fibroblast (CAF) formation (zhang2026esophagealcancerfrom pages 6-7). Single-cell RNA sequencing has identified CXCL13+CD8+ exhausted T cells as predictors of response to neoadjuvant immunochemotherapy (ji2024singlecellprofilingof pages 1-2). PD-L1+ tumor-associated macrophages correlate with clinical benefit from immunotherapy, and CD39-expressing tumor-infiltrating T cells are associated with improved survival and immunotherapy response (chen2025singlecellatlasof pages 5-6, chen2025singlecellatlasof pages 2-3). SPP1+ macrophages have been identified as key drivers of resistance to neoadjuvant chemoimmunotherapy (ji2024singlecellprofilingof pages 1-2).

Advanced Technologies — Single-Cell and Spatial Transcriptomics

Mass cytometry analysis of over 10 million cells from 25 ESCC tumors revealed a compartmentalized immune landscape with reproducible paucity of CD4+ and CD8+ central memory T cells (TCM) in tumor sites (chen2025singlecellatlasof pages 2-3). Single-cell profiling identified 14 major cell subsets including cancer, immune, and stromal cells, with cancer cell differentiation status correlating with treatment response (ji2024singlecellprofilingof pages 1-2). Spatial transcriptomics revealed metastasis-related regions with surrounding vasculature, suggesting new blood vessel recruitment is essential for ESCC metastasis (guo2025singlecellrnasequencing pages 3-3). Two CAF subtypes were identified: extracellular matrix CAFs (eCAFs) and inflammatory CAFs (iCAFs) (yin2025singlecelltranscriptomicanalysis pages 1-2, yin2025singlecelltranscriptomicanalysis pages 14-15).

7. Anatomical Structures Affected

Organ Level

• Primary organ: Esophagus (UBERON:0001043)
• ESCC: Upper and middle esophagus
• EAC: Lower/distal esophagus and gastroesophageal junction
• Secondary involvement: Lymph nodes (regional metastasis), liver, lung, kidney, adrenal gland (distant metastasis) (zhang2026esophagealcancerfrom pages 2-3)
• Body systems: Digestive system (UBERON:0001007)

Tissue and Cell Level

• ESCC: Squamous epithelium (UBERON:0006914); squamous epithelial cells (CL:0000076)
• EAC: Columnar epithelium with intestinal metaplasia (Barrett's esophagus)
• Cell types involved: Epithelial cells, CD8+ T cells, CD4+ T cells, regulatory T cells (CL:0000815), NK cells, macrophages (CL:0000235), dendritic cells, CAFs, endothelial cells, pericytes, MDSCs (zhang2026esophagealcancerfrom pages 2-3, chen2025singlecellatlasof pages 2-3)

Subcellular Level

• Nucleus (GO:0005634) — genomic instability and TP53 dysfunction
• Mitochondria — metabolic reprogramming
• Cell membrane — receptor tyrosine kinases (EGFR, HER2, FGFR)

8. Temporal Development

Onset

• Typical age: Adult-onset, predominantly 50–70 years, with peak incidence in the 60–70 age group (ilic2024globalburdenof pages 4-6).
• Onset pattern: Insidious; early-stage disease is frequently asymptomatic.

Progression

• ESCC stages: Normal epithelium → basal cell hyperplasia → low-grade intraepithelial neoplasia → high-grade intraepithelial neoplasia → invasive carcinoma (zhang2026esophagealcancerfrom pages 1-2).
• EAC stages: Normal → GERD → Barrett's esophagus → LGD → HGD → EAC (li2023molecularbiologyand pages 1-2).
• Staging: AJCC TNM staging system (8th edition) incorporating T (tumor depth), N (nodal status), M (metastasis), grade, and location.
• Progression rate: Variable; some Barrett's esophagus patients progress rapidly while others remain stable. TP53 mutations in BE progressors (46%) vs. nonprogressors (5%) serve as an early predictive marker (zhang2026esophagealcancerfrom pages 6-7).
• Disease course: Progressive without treatment; chronic, often fatal.

9. Inheritance and Population

Epidemiology

The global epidemiological burden of esophageal cancer is summarized in the following table:

Table: This table summarizes the recent global epidemiological burden of esophageal cancer using GLOBOCAN 2022 and GBD 2019/2021 data. It highlights incidence, mortality, geographic concentration, sex disparity, survival, future projections, and major attributable risk factors.

In 2019, there were 534,563 new cases globally (388,827 males, 145,736 females), with an age-standardized incidence rate of 6.5 per 100,000 (ilic2024globalburdenof pages 4-6). East Asia accounted for 53.2% of cases, with China representing 97.6% of those. The highest incidence rates (~17 per 100,000) occurred in Mongolia and Malawi (ilic2024globalburdenof pages 4-6). Age-standardized rates have been declining since 1990 (24.87% decrease in incidence by 2021), though absolute numbers continue to rise due to population growth and aging (zhang2025burdenofesophageal pages 1-2). By 2050, new cases are projected to increase by 80.5% and deaths by 85.4% compared to 2022 levels (qi2024globalesophagealcancer pages 1-2).

Genetic Inheritance

EC is a complex, multifactorial disease with polygenic susceptibility. It does not follow a Mendelian inheritance pattern except in rare syndromes: - Tylosis (Howel-Evans syndrome): Autosomal dominant; associated with RHBDF2 mutations; strongly predisposes to ESCC. - GWAS have identified susceptibility loci including ADH1B, ALDH2, PLCE1, SLC39A6, and others (zhang2026esophagealcancerfrom pages 2-3, OpenTargets Search: esophageal carcinoma).

Population Demographics

• Sex ratio: Males have approximately 3-fold higher incidence and mortality than females across all regions (zhang2026esophagealcancerfrom pages 2-3, ilic2024globalburdenof pages 4-6).
• Geographic distribution: ESCC is most prevalent in the "Asian esophageal cancer belt" (extending from northern Iran through Central Asia to northern China), and in East and Southern Africa. EAC is most common in Western Europe, North America, and Oceania (ilic2024globalburdenof pages 13-15, qi2024globalesophagealcancer pages 1-2).
• Ethnic variation: ESCC predominates in East Asian and Sub-Saharan African populations; EAC is more common in Caucasian populations (li2023molecularbiologyand pages 1-2).

10. Diagnostics

Clinical Tests

• Upper gastrointestinal endoscopy with biopsy is the gold standard for diagnosis (sheikh2023currentstatusand pages 15-16). MAXO:0000130 (endoscopy).
• Endoscopic ultrasound (EUS): Standard technique for locoregional staging (sheikh2023currentstatusand pages 15-16).
• Cross-sectional imaging: CT, MRI, PET/CT for distant staging (rai2023biomarkersforearly pages 6-8).
• Advanced endoscopy: Chromoendoscopy, virtual chromoendoscopy, confocal laser endomicroscopy, volumetric laser endomicroscopy (rai2023biomarkersforearly pages 6-8).

Biomarkers

• HER2 (ERBB2): Positive in 15–29% of EAC; FDA companion diagnostic for trastuzumab (rai2023biomarkersforearly pages 8-9).
• PD-L1: FDA-approved companion diagnostic for immunotherapy; present in ≤27% of EAC tumors (rai2023biomarkersforearly pages 8-9).
• Microsatellite instability (MSI-H)/dMMR: Enhanced sensitivity to immune checkpoint inhibitors (fick2024immunotherapyforresectable pages 7-7).
• Tumor mutational burden (TMB): FDA-approved companion diagnostic for pembrolizumab (rai2023biomarkersforearly pages 1-3).
• Circulating tumor DNA (ctDNA): Emerging prognostic biomarker detected via NGS (rai2023biomarkersforearly pages 6-8, fick2024immunotherapyforresectable pages 9-10).
• DNA methylation markers: Non-invasive approaches including blood cfDNA methylation and esophageal exfoliated cell-based DNA methylation analysis show promise for early detection (rai2023biomarkersforearly pages 6-8).
• 5-hydroxymethylcytosine (5hmC) signatures: Combined with low-pass WGS, achieves AUC of 0.934 for ESCC detection with 82.4% sensitivity and 88.2% specificity.

Screening

• Endoscopy-based screening in high-incidence regions (China, Japan) meets cost-effectiveness criteria and has demonstrated 43% reduction in SCC incidence and 45% reduction in mortality (liu2023epidemiologyofesophageal pages 6-7).
• Cytosponge™: Non-endoscopic swallowable device for Barrett's esophagus detection, combined with TFF3 biomarker immunohistochemistry (sheikh2023currentstatusand pages 15-16).
• Liquid biopsy: Blood, urine, and saliva-based non-invasive screening approaches under development (rai2023biomarkersforearly pages 1-3).

11. Outcome/Prognosis

Survival and Mortality

• 5-year survival rate: Less than 20% overall; as low as 15% in some populations (zhang2025burdenofesophageal pages 1-2, sheikh2023currentstatusand pages 15-16).
• Early detection survival: When detected early, endoscopic removal achieves 5-year survival rates up to 95% (zhang2026esophagealcancerfrom pages 2-3).
• Advanced disease: Metastatic disease treated with first-line chemotherapy achieves median survival of less than 1 year (jazieh2024advancesinimmunotherapy pages 1-3).
• Mortality: 445,391 deaths globally in 2022 with ASMR of 4.30 per 100,000; mortality-to-incidence ratio is high (qi2024globalesophagealcancer pages 1-2).

Prognostic Factors

• Disease stage at diagnosis (most important)
• Histological subtype (ESCC vs. EAC)
• PD-L1 expression and MSI-H/dMMR status for immunotherapy response prediction
• Serum IL-6 levels: Higher levels predict worse prognosis and increased immune-related adverse events with immunotherapy
• CD39+ tumor-infiltrating T cells correlate with favorable prognosis (chen2025singlecellatlasof pages 2-3)
• CXCL13+CD8+ exhausted T cells predict improved response to neoadjuvant immunochemotherapy (ji2024singlecellprofilingof pages 1-2)

12. Treatment

Pharmacotherapy

Chemotherapy

• First-line regimens: Fluorinated pyrimidine plus platinum agent (cisplatin or oxaliplatin) ± taxane (jazieh2024advancesinimmunotherapy pages 1-3).
• Neoadjuvant regimens: CROSS regimen (carboplatin/paclitaxel + radiotherapy); FLOT regimen (5-FU/leucovorin/oxaliplatin/docetaxel) for perioperative EAC treatment (li2023molecularbiologyand pages 1-2, fick2024immunotherapyforresectable pages 7-7).

Immunotherapy

• Pembrolizumab (anti-PD-1): FDA-approved (March 2021, KEYNOTE-590 trial) for first-line advanced EC combined with chemotherapy (rai2023biomarkersforearly pages 8-9, jazieh2024advancesinimmunotherapy pages 1-3). MAXO:0001287 (immune checkpoint inhibitor therapy).
• Nivolumab (anti-PD-1): FDA-approved for adjuvant use after neoadjuvant chemoradiotherapy and surgery in patients with residual disease (CheckMate 577); improved median DFS 22.4 vs. 11.0 months, particularly in ESCC (29.7 vs. 11.0 months) (fick2024immunotherapyforresectable pages 7-7, zhang2026esophagealcancerfrom pages 21-21).
• Anti-PD-1 plus platinum-based chemotherapy has replaced chemotherapy alone as the standard first-line treatment for most advanced EC patients (zhang2026esophagealcancerfrom pages 21-21).
• Pathologic complete response rates with ICI plus chemoradiotherapy reach up to 60% in early-phase trials, with highest rates in ESCC and dMMR tumors (fick2024immunotherapyforresectable pages 1-2).

Targeted Therapy

• Trastuzumab: HER2-directed therapy for HER2-positive EAC (15–29% of cases); FDA companion diagnostic required (rai2023biomarkersforearly pages 8-9). MAXO:0001298 (HER2 targeted therapy).
• CLDN18.2-targeting therapies: Zolbetuximab (anti-CLDN18.2 antibody) and AZD6422 (armored CAR-T targeting CLDN18.2) are in clinical development for CLDN18.2+ esophagogastric cancers.
• EGFR inhibitors: Cetuximab studied but has not significantly improved OS in meta-analyses despite EGFR overexpression in 20–50% of EAC tumors (rai2023biomarkersforearly pages 8-9).

Surgical Interventions

• Esophagectomy: Radical resection remains a cornerstone for resectable disease, typically after neoadjuvant therapy. R0 resection rates with neoadjuvant immunotherapy approaches are high (up to 98%) (fick2024immunotherapyforresectable pages 4-5). MAXO:0000004 (surgical procedure).
• Endoscopic treatments: EMR (endoscopic mucosal resection) and ESD (endoscopic submucosal dissection) for early-stage disease without lymph node involvement (sheikh2023currentstatusand pages 15-16). MAXO:0000130 (endoscopy).

Experimental Treatments

• Neoadjuvant chemo-immunotherapy: Phase III trials investigating perioperative ICI combinations ongoing (fick2024immunotherapyforresectable pages 1-2, fick2024immunotherapyforresectable pages 5-7).
• CAR-T therapy: Mesothelin-targeted (M28z1XXPD1DNR) CAR-T for peritoneal carcinomatosis (NCT06623396); CLDN18.2-targeting CAR-T (AZD6422) in clinical development.
• Personalized neoantigen vaccines: NCT05307835 investigating tumor-specific antigen vaccination (fick2024immunotherapyforresectable pages 9-10).
• Anti-TIGIT combinations: Multiple clinical trials combining TIGIT blockade with anti-PD-1 for esophagogastric cancers.

Treatment Outcomes

• Neoadjuvant chemoradiotherapy with immunotherapy: pooled pCR rates of 31.4%, MPR rates of 48.9% (fick2024immunotherapyforresectable pages 5-7).
• Immunotherapy addition to chemoradiotherapy associated with higher pCR (29% vs. 21%), improved nodal downstaging (50% vs. 40%), and longer median OS (69.1 vs. 56.3 months) (fick2024immunotherapyforresectable pages 5-7).
• ICI response rates remain ≤30% overall, with immune-related adverse events in 17% of cases (Grade 3+) (rai2023biomarkersforearly pages 8-9).

13. Prevention

Primary Prevention

• Tobacco cessation and alcohol reduction are the most impactful strategies, as smoking and alcohol account for ~90% of ESCC in Western countries (jiang2023globaltrendsin pages 12-13).
• Dietary modification: Increased intake of fresh fruits and vegetables; avoidance of moldy foods and nitrosamine-containing foods (qi2024globalesophagealcancer pages 1-2).
• Weight management: Reducing obesity to lower EAC risk (high BMI accounts for 18.8–19.3% of DALYs) (ilic2024globalburdenof pages 6-10).
• GERD management: Proton pump inhibitors and lifestyle modifications to prevent Barrett's esophagus progression (sheikh2023currentstatusand pages 15-16).

Secondary Prevention (Screening and Early Detection)

• Endoscopic screening in high-incidence populations has demonstrated significant mortality reduction (45% in community-based Chinese studies) (liu2023epidemiologyofesophageal pages 6-7).
• Cytosponge™ combined with biomarker assays for non-endoscopic Barrett's screening (sheikh2023currentstatusand pages 15-16).
• Risk stratification using genetic markers, clinical factors, and molecular biomarkers for targeted screening.
• Endoscopy-based early diagnosis in China and Japan has advanced endoscopic methods as definitive treatments with remarkable efficacy (zhang2026esophagealcancerfrom pages 1-2).

Chemoprevention

• Aspirin and proton pump inhibitors have shown promising results in chemoprevention of EAC from Barrett's esophagus (sheikh2023currentstatusand pages 15-16).

14. Other Species / Natural Disease

Esophageal cancer naturally occurs in various animal species, though it is less extensively documented than in humans. The condition has been observed in: - Dogs (Canis lupus familiaris): Esophageal carcinoma, though rare, has been documented; spirocercosis (Spirocerca lupi) infection is a known risk factor for esophageal sarcoma in dogs. - Cattle (Bos taurus): Esophageal papillomas and carcinomas associated with bovine papillomavirus and bracken fern consumption.

15. Model Organisms

Cell Lines

Extensively used ESCC cell lines include the KYSE series (KYSE-30, KYSE-150, KYSE-180, KYSE-450, KYSE-510), TE-1, ECA-109, and KYSE-770, with the normal epithelial line Het-1a as control. Whole exome and RNA sequencing have characterized their genomic landscape, revealing TMB ranging from 48.7 to 70.4 mut/MB, with mutations in Hippo, Notch, PI3K, RTK-Ras, and Wnt pathways across all cancer cell lines (zhang2025thegenomiclandscape pages 4-7). Human esophageal squamous cell lines KYSE140, KYSE150, KYSE450, KYSE510, KYSE30, KYSE70, and KYSE410 are widely used (liu2023spatialtranscriptomicsanalysis pages 16-17).

Mouse Models

• 4-NQO (4-nitroquinoline-1-oxide)-induced spontaneous ESCC mouse model: Chemical carcinogen administered in drinking water to induce ESCC, recapitulating the multistep carcinogenesis process. This model has been used to validate therapeutic targets including CCL18 blockade.
• Xenograft models: CB17 SCID immunodeficient mice used for subcutaneous and orthotopic tumor growth studies (liu2023spatialtranscriptomicsanalysis pages 16-17).
• Patient-derived xenograft (PDX) models: Preserve patient tumor features and are used for drug efficacy testing and personalized medicine approaches.

Organoid Models

Patient-derived organoids (PDOs) maintain in Matrigel culture for 10–14 days and can be genetically modified via lentivirus-mediated transduction. PDOs have been used for coculture experiments to test T cell cytotoxicity (liu2023spatialtranscriptomicsanalysis pages 16-17, chen2025singlecellatlasof pages 3-5). Organoid models are increasingly used in the research and development of antitumor drugs and personalized medicine.

Model Limitations

Cell line-derived xenograft models lack patient tumor heterogeneity and immune microenvironment characteristics. PDX and organoid models better preserve patient features but remain limited in recapitulating the full immune microenvironment, particularly the adaptive immune response.

Summary

Esophageal carcinoma remains one of the most lethal and challenging cancers globally, with high mortality rates and poor overall prognosis. The two major subtypes, ESCC and EAC, exhibit distinct epidemiological patterns, risk factor profiles, molecular landscapes, and geographic distributions. Recent advances in single-cell and spatial transcriptomics have revealed unprecedented detail about the tumor microenvironment, identifying cell-type-specific mechanisms of immune evasion and treatment resistance. The integration of immune checkpoint inhibitors, particularly anti-PD-1 antibodies, into treatment paradigms has significantly improved outcomes for both subtypes, with adjuvant nivolumab and first-line pembrolizumab plus chemotherapy now established as standard-of-care options. Emerging therapeutic modalities including CAR-T cell therapy, personalized neoantigen vaccines, and novel checkpoint combinations hold promise for further improvements. Primary prevention through tobacco cessation, alcohol reduction, and dietary modification remains the most effective strategy for reducing the global burden of this disease, while advances in non-invasive screening technologies and liquid biopsy approaches may enable earlier detection and improved survival outcomes in the future.

References

1. (qi2024globalesophagealcancer pages 1-2): Ling Qi, Mengfei Sun, Weixin Liu, Xuefeng Zhang, Yongjun Yu, Ziqiang Tian, Zhiyu Ni, Rongshou Zheng, and Yong Li. Global esophageal cancer epidemiology in 2022 and predictions for 2050: a comprehensive analysis and projections based on globocan data. Chinese Medical Journal, 137:3108-3116, Dec 2024. URL: https://doi.org/10.1097/cm9.0000000000003420, doi:10.1097/cm9.0000000000003420. This article has 75 citations and is from a peer-reviewed journal.

2. (zhang2026esophagealcancerfrom pages 1-2): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

3. (sheikh2023currentstatusand pages 15-16): Mahdi Sheikh, Gholamreza Roshandel, Valerie McCormack, and Reza Malekzadeh. Current status and future prospects for esophageal cancer. Cancers, 15:765, Jan 2023. URL: https://doi.org/10.3390/cancers15030765, doi:10.3390/cancers15030765. This article has 294 citations.

4. (OpenTargets Search: esophageal carcinoma): Open Targets Query (esophageal carcinoma, 40 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (li2023molecularbiologyand pages 1-2): Shulin Li, Sanne Johanna Maria Hoefnagel, and Kausilia Krishnawatie Krishnadath. Molecular biology and clinical management of esophageal adenocarcinoma. Cancers, 15:5410, Nov 2023. URL: https://doi.org/10.3390/cancers15225410, doi:10.3390/cancers15225410. This article has 24 citations.

6. (zhang2026esophagealcancerfrom pages 6-7): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

7. (zhang2026esophagealcancerfrom pages 9-10): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

8. (zhang2026esophagealcancerfrom pages 2-3): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

9. (li2023molecularbiologyand pages 6-8): Shulin Li, Sanne Johanna Maria Hoefnagel, and Kausilia Krishnawatie Krishnadath. Molecular biology and clinical management of esophageal adenocarcinoma. Cancers, 15:5410, Nov 2023. URL: https://doi.org/10.3390/cancers15225410, doi:10.3390/cancers15225410. This article has 24 citations.

10. (liu2023epidemiologyofesophageal pages 8-9): Chun‐Quan Liu, Yun‐Lei Ma, Qi Qin, Pei‐Hao Wang, Yi Luo, Peng‐Fei Xu, and Yong Cui. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thoracic Cancer, 14:3-11, Dec 2023. URL: https://doi.org/10.1111/1759-7714.14745, doi:10.1111/1759-7714.14745. This article has 457 citations.

11. (ilic2024globalburdenof pages 6-10): Irena Ilic, Ivana Zivanovic Macuzic, Ana Ravic-Nikolic, Milena Ilic, and Vesna Milicic. Global burden of esophageal cancer and its risk factors: a systematic analysis of the global burden of disease study 2019. Life, 15:24, Dec 2024. URL: https://doi.org/10.3390/life15010024, doi:10.3390/life15010024. This article has 15 citations.

12. (ilic2024globalburdenof pages 4-6): Irena Ilic, Ivana Zivanovic Macuzic, Ana Ravic-Nikolic, Milena Ilic, and Vesna Milicic. Global burden of esophageal cancer and its risk factors: a systematic analysis of the global burden of disease study 2019. Life, 15:24, Dec 2024. URL: https://doi.org/10.3390/life15010024, doi:10.3390/life15010024. This article has 15 citations.

13. (fick2024immunotherapyforresectable pages 9-10): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

14. (rai2023biomarkersforearly pages 8-9): Vikrant Rai, Joe Abdo, and Devendra K. Agrawal. Biomarkers for early detection, prognosis, and therapeutics of esophageal cancers. International Journal of Molecular Sciences, 24:3316, Feb 2023. URL: https://doi.org/10.3390/ijms24043316, doi:10.3390/ijms24043316. This article has 73 citations.

15. (zhang2025thegenomiclandscape pages 4-7): Chao Zhang, Chenghao Li, Jian Zhong Su, Kuaile Zhao, Longlong Shao, and Jiaying Deng. The genomic landscape of esophageal squamous cell carcinoma cell lines. Cancer Cell International, May 2025. URL: https://doi.org/10.1186/s12935-025-03686-1, doi:10.1186/s12935-025-03686-1. This article has 7 citations and is from a peer-reviewed journal.

16. (zhang2026esophagealcancerfrom pages 8-9): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

17. (li2023molecularbiologyand pages 16-17): Shulin Li, Sanne Johanna Maria Hoefnagel, and Kausilia Krishnawatie Krishnadath. Molecular biology and clinical management of esophageal adenocarcinoma. Cancers, 15:5410, Nov 2023. URL: https://doi.org/10.3390/cancers15225410, doi:10.3390/cancers15225410. This article has 24 citations.

18. (zhang2026esophagealcancerfrom pages 30-31): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

19. (zhang2026esophagealcancerfrom pages 21-21): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

20. (jazieh2024advancesinimmunotherapy pages 1-3): Khalid Jazieh, Harry H Yoon, and Mojun Zhu. Advances in immunotherapy in esophagogastric cancer. Jun 2024. URL: https://doi.org/10.1016/j.hoc.2024.02.002, doi:10.1016/j.hoc.2024.02.002. This article has 1 citations.

21. (chen2025singlecellatlasof pages 5-6): Xiankai Chen, Yahui Zhao, Yuhao Wang, Xiliang Wang, Yuhao Liu, Zhihua Liu, and Yin Li. Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response. Signal Transduction and Targeted Therapy, Oct 2025. URL: https://doi.org/10.1038/s41392-025-02446-x, doi:10.1038/s41392-025-02446-x. This article has 8 citations and is from a peer-reviewed journal.

22. (maslenkina2023signalingpathwaysin pages 14-16): Ksenia Maslenkina, Liudmila Mikhaleva, Maxim Naumenko, Rositsa Vandysheva, Michail Gushchin, Dmitri Atiakshin, Igor Buchwalow, and Markus Tiemann. Signaling pathways in the pathogenesis of barrett’s esophagus and esophageal adenocarcinoma. International Journal of Molecular Sciences, May 2023. URL: https://doi.org/10.3390/ijms24119304, doi:10.3390/ijms24119304. This article has 26 citations.

23. (jiang2023globaltrendsin pages 12-13): Yu Jiang, Yuechun Lin, Yaokai Wen, Wenhai Fu, Rui Wang, Jiaxi He, Jianrong Zhang, Zhufeng Wang, Fan Ge, Zhenyu Huo, Runchen Wang, Haoxin Peng, Xiangrong Wu, Jianxing He, and Shuben Li. Global trends in the burden of esophageal cancer, 1990−2019: results from the global burden of disease study 2019. Journal of Thoracic Disease, 15:348-364, Feb 2023. URL: https://doi.org/10.21037/jtd-22-856, doi:10.21037/jtd-22-856. This article has 43 citations and is from a peer-reviewed journal.

24. (rai2023biomarkersforearly pages 6-8): Vikrant Rai, Joe Abdo, and Devendra K. Agrawal. Biomarkers for early detection, prognosis, and therapeutics of esophageal cancers. International Journal of Molecular Sciences, 24:3316, Feb 2023. URL: https://doi.org/10.3390/ijms24043316, doi:10.3390/ijms24043316. This article has 73 citations.

25. (fick2024immunotherapyforresectable pages 4-5): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

26. (ji2024singlecellprofilingof pages 1-2): Gang Ji, Qi Yang, Song Wang, Xiaolong Yan, Qiuxiang Ou, Li Gong, Jinbo Zhao, Yongan Zhou, Feng Tian, Jie Lei, Xiaorong Mu, Jian Wang, Tao Wang, Xiaoping Wang, Jianyong Sun, Jipeng Zhang, Chenghui Jia, Tao Jiang, Ming-gao Zhao, and Qiang Lu. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma. Genome Medicine, Apr 2024. URL: https://doi.org/10.1186/s13073-024-01320-9, doi:10.1186/s13073-024-01320-9. This article has 52 citations and is from a highest quality peer-reviewed journal.

27. (chen2025singlecellatlasof pages 2-3): Xiankai Chen, Yahui Zhao, Yuhao Wang, Xiliang Wang, Yuhao Liu, Zhihua Liu, and Yin Li. Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response. Signal Transduction and Targeted Therapy, Oct 2025. URL: https://doi.org/10.1038/s41392-025-02446-x, doi:10.1038/s41392-025-02446-x. This article has 8 citations and is from a peer-reviewed journal.

28. (guo2025singlecellrnasequencing pages 3-3): Wei Guo, Bolun Zhou, Lizhou Dou, Lei Guo, Yong Li, Jianjun Qin, Zhen Wang, Qilin Huai, Xuemin Xue, Yin Li, Jianming Ying, Qi Xue, Shugeng Gao, and Jie He. Single-cell rna sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases. Experimental & Molecular Medicine, 57:59-71, Jan 2025. URL: https://doi.org/10.1038/s12276-024-01369-x, doi:10.1038/s12276-024-01369-x. This article has 15 citations and is from a peer-reviewed journal.

29. (yin2025singlecelltranscriptomicanalysis pages 1-2): Xiaolei Yin, Xiaopeng Li, Lili Mi, Jiaojiao Hou, and Fei Yin. Single-cell transcriptomic analysis reveals epithelial and microenvironmental heterogeneity in small cell carcinoma of the esophagus. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1672587, doi:10.3389/fimmu.2025.1672587. This article has 1 citations and is from a peer-reviewed journal.

30. (yin2025singlecelltranscriptomicanalysis pages 14-15): Xiaolei Yin, Xiaopeng Li, Lili Mi, Jiaojiao Hou, and Fei Yin. Single-cell transcriptomic analysis reveals epithelial and microenvironmental heterogeneity in small cell carcinoma of the esophagus. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1672587, doi:10.3389/fimmu.2025.1672587. This article has 1 citations and is from a peer-reviewed journal.

31. (zhang2025burdenofesophageal pages 1-2): Chengcheng Zhang, Linzhi Chen, Yuqi Xiu, Hongling Zhang, Yuejuan Zhang, and Wenjuan Ying. Burden of esophageal cancer in global, regional and national regions from 1990 to 2021 and its projection until 2050: results from the gbd study 2021. Frontiers in Oncology, Jan 2025. URL: https://doi.org/10.3389/fonc.2024.1518567, doi:10.3389/fonc.2024.1518567. This article has 17 citations.

32. (ilic2024globalburdenof pages 2-4): Irena Ilic, Ivana Zivanovic Macuzic, Ana Ravic-Nikolic, Milena Ilic, and Vesna Milicic. Global burden of esophageal cancer and its risk factors: a systematic analysis of the global burden of disease study 2019. Life, 15:24, Dec 2024. URL: https://doi.org/10.3390/life15010024, doi:10.3390/life15010024. This article has 15 citations.

33. (ilic2024globalburdenof pages 13-15): Irena Ilic, Ivana Zivanovic Macuzic, Ana Ravic-Nikolic, Milena Ilic, and Vesna Milicic. Global burden of esophageal cancer and its risk factors: a systematic analysis of the global burden of disease study 2019. Life, 15:24, Dec 2024. URL: https://doi.org/10.3390/life15010024, doi:10.3390/life15010024. This article has 15 citations.

34. (fick2024immunotherapyforresectable pages 7-7): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

35. (rai2023biomarkersforearly pages 1-3): Vikrant Rai, Joe Abdo, and Devendra K. Agrawal. Biomarkers for early detection, prognosis, and therapeutics of esophageal cancers. International Journal of Molecular Sciences, 24:3316, Feb 2023. URL: https://doi.org/10.3390/ijms24043316, doi:10.3390/ijms24043316. This article has 73 citations.

36. (liu2023epidemiologyofesophageal pages 6-7): Chun‐Quan Liu, Yun‐Lei Ma, Qi Qin, Pei‐Hao Wang, Yi Luo, Peng‐Fei Xu, and Yong Cui. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thoracic Cancer, 14:3-11, Dec 2023. URL: https://doi.org/10.1111/1759-7714.14745, doi:10.1111/1759-7714.14745. This article has 457 citations.

37. (fick2024immunotherapyforresectable pages 1-2): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

38. (fick2024immunotherapyforresectable pages 5-7): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

39. (liu2023spatialtranscriptomicsanalysis pages 16-17): Xuejiao Liu, Simin Zhao, Keke Wang, Liting Zhou, Ming Jiang, Yunfeng Gao, Ran Yang, Shiwen Yan, Wen Zhang, Bingbing Lu, Feifei Liu, Ran Zhao, Wenting Liu, Zihan Zhang, Kangdong Liu, Xiang Li, and Zigang Dong. Spatial transcriptomics analysis of esophageal squamous precancerous lesions and their progression to esophageal cancer. Nature Communications, Aug 2023. URL: https://doi.org/10.1038/s41467-023-40343-5, doi:10.1038/s41467-023-40343-5. This article has 62 citations and is from a highest quality peer-reviewed journal.

40. (chen2025singlecellatlasof pages 3-5): Xiankai Chen, Yahui Zhao, Yuhao Wang, Xiliang Wang, Yuhao Liu, Zhihua Liu, and Yin Li. Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response. Signal Transduction and Targeted Therapy, Oct 2025. URL: https://doi.org/10.1038/s41392-025-02446-x, doi:10.1038/s41392-025-02446-x. This article has 8 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01